Tuesday, November 26, 2024
HomeTagsNektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

Nektar Therapeutics announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of rezpegaldesleukin in adults with moderately-to-severely active systemic lupus erythematosus (SLE)...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics